{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:05:03Z","timestamp":1789416303227,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ContraFect Corporation","award":["IDSEP160030"],"award-info":[{"award-number":["IDSEP160030"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lundquist Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lysins (cell wall hydrolases) targeting gram-negative organisms require engineering to permeabilize the outer membrane and access subjacent peptidoglycan to facilitate killing. In the current study, the potential clinical utility for the engineered lysin CF-370 was examined in vitro and in vivo against gram-negative pathogens important in human infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Minimum inhibitory concentration (MICs) and bactericidal activity were determined using standard methods. An in vivo proof-of-concept efficacy study was conducted using a rabbit acute pneumonia model caused by Pseudomonas aeruginosa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CF-370 exhibited potent antimicrobial activity, with MIC50\/90 values (in \u00b5g\/mL) for: P aeruginosa, 1\/2; Acinetobacter baumannii, 1\/1; Escherichia coli, 0.25\/1; Klebsiella pneumoniae, 2\/4; Enterobacter cloacae 1\/4; and Stenotrophomonas maltophilia 2\/8. CF-370 furthermore demonstrated bactericidal activity, activity in serum, a low propensity for resistance, anti-biofilm activity, and synergy with antibiotics. In the pneumonia model, CF-370 alone decreased bacterial densities in lungs, kidneys, and spleen versus vehicle control, and demonstrated significantly increased efficacy when combined with meropenem (vs either agent alone).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CF-370 is the first engineered lysin described with potent broad-spectrum in vitro activity against multiple clinically relevant gram-negative pathogens, as well as potent in vivo efficacy in an animal model of severe invasive multisystem infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiae027","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T16:52:39Z","timestamp":1707497559000},"page":"309-318","source":"Crossref","is-referenced-by-count":13,"title":["The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental\n                    <i>Pseudomonas aeruginosa<\/i>\n                    Pneumonia"],"prefix":"10.1093","volume":"230","author":[{"given":"Karen","family":"Sauve","sequence":"first","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Watson","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun T","family":"Oh","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Swift","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Vila-Farres","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam","family":"Abdelhady","sequence":"additional","affiliation":[{"name":"The Lundquist Institute, Harbor-UCLA Medical Center , Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Q","family":"Xiong","sequence":"additional","affiliation":[{"name":"The Lundquist Institute, Harbor-UCLA Medical Center , Torrance, California"},{"name":"Geffen School of Medicine, University of California , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"LeHoux","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Woodnutt","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S","family":"Bayer","sequence":"additional","affiliation":[{"name":"The Lundquist Institute, Harbor-UCLA Medical Center , Torrance, California"},{"name":"Geffen School of Medicine, University of California , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-573X","authenticated-orcid":false,"given":"Raymond","family":"Schuch","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2024081523525207100_jiae027-B1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2024081523525207100_jiae027-B2","author":"World Health Organization"},{"key":"2024081523525207100_jiae027-B3","doi-asserted-by":"crossref","first-page":"841905","DOI":"10.3389\/fmicb.2022.841905","article-title":"Direct lytic agents: novel, rapidly acting potential antimicrobial treatment modalities for systemic use in the era of rising antibiotic resistance","volume":"13","author":"Schuch","year":"2022","journal-title":"Front Microbiol"},{"key":"2024081523525207100_jiae027-B4","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1073\/pnas.061038398","article-title":"Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme","volume":"98","author":"Nelson","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024081523525207100_jiae027-B5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature01026","article-title":"A bacteriolytic agent that detects and kills Bacillus anthracis","volume":"418","author":"Schuch","year":"2002","journal-title":"Nature"},{"key":"2024081523525207100_jiae027-B6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/infdis\/jit637","article-title":"Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus\u2013induced murine bacteremia","volume":"209","author":"Schuch","year":"2014","journal-title":"J Infect Dis"},{"key":"2024081523525207100_jiae027-B7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biotechadv.2017.12.009","article-title":"Synthetic biology of modular endolysins","volume":"36","author":"Gerstmans","year":"2018","journal-title":"Biotechnol Adv"},{"key":"2024081523525207100_jiae027-B8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/v13040680","article-title":"The advantages and challenges of using endolysins in a clinical setting","volume":"13","author":"Murray","year":"2021","journal-title":"Viruses"},{"key":"2024081523525207100_jiae027-B9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mib.2016.05.006","article-title":"Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments","volume":"33","author":"Wittekind","year":"2016","journal-title":"Curr Opin Microbiol"},{"key":"2024081523525207100_jiae027-B10","author":"ContraFect"},{"key":"2024081523525207100_jiae027-B11","doi-asserted-by":"crossref","first-page":"a000414","DOI":"10.1101\/cshperspect.a000414","article-title":"The bacterial cell envelope","volume":"2","author":"Silhavy","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2024081523525207100_jiae027-B12","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1021\/acsinfecdis.1c00222","article-title":"Membrane-permeable antibacterial enzyme against multidrug-resistant Acinetobacter baumannii","volume":"7","author":"Chen","year":"2021","journal-title":"ACS Infect Dis"},{"key":"2024081523525207100_jiae027-B13","doi-asserted-by":"crossref","first-page":"eaaz1136","DOI":"10.1126\/sciadv.aaz1136","article-title":"A VersaTile-driven platform for rapid hit-to-lead development of engineered lysins","volume":"6","author":"Gerstmans","year":"2020","journal-title":"Sci Adv"},{"key":"2024081523525207100_jiae027-B14","doi-asserted-by":"crossref","first-page":"988522","DOI":"10.3389\/fmicb.2022.988522","article-title":"Engineering of lysin by fusion of antimicrobial peptide (cecropin A) enhances its antibacterial properties against multidrug-resistant Acinetobacter baumannii","volume":"13","author":"Islam","year":"2022","journal-title":"Front Microbiol"},{"key":"2024081523525207100_jiae027-B15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10482-016-0806-2","article-title":"Enhancement of the direct antimicrobial activity of lysep3 against Escherichia coli by inserting cationic peptides into its C terminus","volume":"110","author":"Ma","year":"2017","journal-title":"Antonie Van Leeuwenhoek"},{"key":"2024081523525207100_jiae027-B16","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1128\/AAC.02668-14","article-title":"Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa","volume":"58","author":"Briers","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B17","doi-asserted-by":"crossref","first-page":"e0151521","DOI":"10.1128\/AEM.01515-21","article-title":"Engineering a lysin with intrinsic antibacterial activity (LysMK34) by cecropin A fusion enhances its antibacterial properties against Acinetobacter baumannii","volume":"88","author":"Abdelkader","year":"2022","journal-title":"Appl Environ Microbiol"},{"key":"2024081523525207100_jiae027-B18","doi-asserted-by":"crossref","first-page":"e01379-14","DOI":"10.1128\/mBio.01379-14","article-title":"Engineered endolysin-based \u201cartilysins\u201d to combat multidrug-resistant gram-negative pathogens","volume":"5","author":"Briers","year":"2014","journal-title":"MBio"},{"key":"2024081523525207100_jiae027-B19","doi-asserted-by":"crossref","first-page":"821936","DOI":"10.3389\/fmicb.2022.821936","article-title":"Combination effect of engineered endolysin EC340 with antibiotics","volume":"13","author":"Hong","year":"2022","journal-title":"Front Microbiol"},{"key":"2024081523525207100_jiae027-B20","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1021\/acsinfecdis.1c00497","article-title":"Intrinsic antimicrobial peptide facilitates a new broad-Spectrum lysin LysP53 to kill Acinetobacter baumannii in vitro and in a mouse burn infection model","volume":"7","author":"Li","year":"2021","journal-title":"ACS Infect Dis"},{"key":"2024081523525207100_jiae027-B21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2217\/fmb.15.8","article-title":"Breaking barriers: expansion of the use of endolysins as novel antibacterials against gram-negative bacteria","volume":"10","author":"Briers","year":"2015","journal-title":"Future Microbiol"},{"key":"2024081523525207100_jiae027-B22","volume-title":"Performance standards for antimicrobial susceptibility testing, document M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2023","edition":"33rd ed"},{"key":"2024081523525207100_jiae027-B23","volume-title":"Performance standards for antimicrobial susceptibility testing, document M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2020","edition":"30th ed"},{"key":"2024081523525207100_jiae027-B24","volume-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"1999"},{"key":"2024081523525207100_jiae027-B25","author":"Lehoux"},{"key":"2024081523525207100_jiae027-B26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fmicb.2014.00643","article-title":"Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria","volume":"5","author":"Olaitan","year":"2014","journal-title":"Front Microbiol"},{"key":"2024081523525207100_jiae027-B27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/microorganisms10020445","article-title":"Exploration of bacterial re-growth as in vitro phenomenon affecting methods for analysis of the antimicrobial activity of chimeric bacteriophage endolysins","volume":"10","author":"Kaspar","year":"2022","journal-title":"Microorganisms"},{"key":"2024081523525207100_jiae027-B28","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/antibiotics10121497","article-title":"Treating bacterial infections with bacteriophage-based enzybiotics: in vitro, in vivo and clinical application","volume":"10","author":"Danis-Wlodarczyk","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2024081523525207100_jiae027-B29","author":"Bautz"},{"key":"2024081523525207100_jiae027-B30","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1128\/AAC.04641-14","article-title":"Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model","volume":"59","author":"Lood","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B31","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1128\/AAC.02972-15","article-title":"Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii","volume":"60","author":"Thandar","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fmicb.2016.00208","article-title":"Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad anti-gram-negative bacterial activity","volume":"7","author":"Oliveira","year":"2016","journal-title":"Front Microbiol"},{"key":"2024081523525207100_jiae027-B33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00253-011-3104-y","article-title":"Antibacterial activity of Acinetobacter baumannii phage varphiAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria","volume":"90","author":"Lai","year":"2011","journal-title":"Appl Microbiol Biotechnol"},{"key":"2024081523525207100_jiae027-B34","doi-asserted-by":"crossref","first-page":"e01311-20","DOI":"10.1128\/AEM.01311-20","article-title":"Lysin LysMK34 of Acinetobacter baumannii bacteriophage PMK34 has a turgor pressure-dependent intrinsic antibacterial activity and reverts colistin resistance","volume":"86:","author":"Abdelkader","year":"2020","journal-title":"Appl Environ Microbiol"},{"key":"2024081523525207100_jiae027-B35","doi-asserted-by":"crossref","first-page":"e108376","DOI":"10.1371\/journal.pone.0108376","article-title":"A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids","volume":"9","author":"Oliveira","year":"2014","journal-title":"PLoS One"},{"key":"2024081523525207100_jiae027-B36","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1128\/AAC.00285-16","article-title":"Efficacy of artilysin art-175 against resistant and persistent Acinetobacter baumannii","volume":"60","author":"Defraine","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B37","doi-asserted-by":"crossref","first-page":"816","DOI":"10.4014\/jmb.2205.05009","article-title":"Bactericidal effect of cecropin A fused endolysin on drug-resistant gram-negative pathogens","volume":"32","author":"Lim","year":"2022","journal-title":"J Microbiol Biotechnol"},{"key":"2024081523525207100_jiae027-B38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/antibiotics9020074","article-title":"Gram-negative bacterial lysins","volume":"9","author":"Ghose","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2024081523525207100_jiae027-B39","doi-asserted-by":"crossref","first-page":"e02666-16","DOI":"10.1128\/AAC.02666-16","article-title":"Bacteriophage lysin CF-301, a potent antistaphylococcal biofilm agent","volume":"61","author":"Schuch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fmicb.2017.00293","article-title":"A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa","volume":"8","author":"Guo","year":"2017","journal-title":"Front Microbiol"},{"key":"2024081523525207100_jiae027-B41","doi-asserted-by":"crossref","first-page":"e00886-18","DOI":"10.1128\/AEM.00886-18","article-title":"Antibacterial effects of phage lysin LysGH15 on planktonic cells and biofilms of diverse staphylococci","volume":"84:","author":"Zhang","year":"2018","journal-title":"Appl Environ Microbiol"},{"key":"2024081523525207100_jiae027-B42","doi-asserted-by":"crossref","first-page":"e0058822","DOI":"10.1128\/aac.00588-22","article-title":"Activity of exebacase (CF-301) against biofilms formed by Staphylococcus epidermidis strains isolated from prosthetic joint infections","volume":"66","author":"Souche","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3389\/fmicb.2019.00913","article-title":"Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents\u2014how P. aeruginosa can escape antibiotics","volume":"10","author":"Ciofu","year":"2019","journal-title":"Front Microbiol"},{"key":"2024081523525207100_jiae027-B44","doi-asserted-by":"crossref","first-page":"e01885-19","DOI":"10.1128\/AAC.01885-19","article-title":"Exebacase demonstrates in vitro synergy with a broad range of antibiotics against both methicillin-resistant and methicillin-susceptible Staphylococcus aureus","volume":"64","author":"Watson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B45","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2217\/fmb-2018-0077","article-title":"Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus","volume":"13","author":"Letrado","year":"2018","journal-title":"Future Microbiol"},{"key":"2024081523525207100_jiae027-B46","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1128\/AAC.01118-16","article-title":"Antibiofilm activity and synergistic inhibition of Staphylococcus aureus biofilms by bactericidal protein P128 in combination with antibiotics","volume":"60","author":"Nair","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B47","doi-asserted-by":"crossref","first-page":"e0505022","DOI":"10.1128\/spectrum.05050-22","article-title":"Exploiting broad-spectrum chimeric lysin to cooperate with mupirocin against Staphylococcus aureus\u2013induced skin infections and delay the development of mupirocin resistance","volume":"11","author":"Duan","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2024081523525207100_jiae027-B48","doi-asserted-by":"crossref","first-page":"e02616-18","DOI":"10.1128\/AAC.02616-18","article-title":"Postantibiotic and sub-MIC effects of exebacase (lysin CF-301) enhance antimicrobial activity against Staphylococcus aureus","volume":"63:","author":"Oh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081523525207100_jiae027-B49","author":"ContraFect"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae027\/56795636\/jiae027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/2\/309\/58809212\/jiae027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/2\/309\/58809212\/jiae027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T19:54:25Z","timestamp":1723751665000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/2\/309\/7608873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae027","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,15]]},"published":{"date-parts":[[2024,2,15]]}}}